Clinical trial
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent…
NCT00005085 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005085 |
|---|---|
| Title | Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer |
| Official title | A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | becatecarin |
| Enrollment | 37 |
| Start date | Feb 1, 2000 |
| Primary completion | Jun 1, 2002 |
| First posted | Mar 16, 2004 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: